Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04457089 · ClinicalTrials.gov registry record · Early Phase 1
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
A Early Phase 1 study of Recurrent Ovarian Cancer and Platinum-sensitive Ovarian Cancer, sponsored by Marc Goodman.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04457089: Completed Early Phase 1 study of Recurrent Ovarian Cancer and Platinum-sensitive Ovarian Cancer, sponsored by Marc Goodman.
NCT04457089 is a Early Phase 1 study of Recurrent Ovarian Cancer and Platinum-sensitive Ovarian Cancer that has completed, run by Marc Goodman. The registered enrollment target is 18 participants, below the 188-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04457089, a Early Phase 1 study of Recurrent Ovarian Cancer and Platinum-sensitive Ovarian Cancer, has completed, sponsored by Marc Goodman.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.
Primary Outcome
Percentage of patients who complete the simvastatin intervention with at least 85% compliance during Carboplatin and Doxil chemotherapy.
Conditions Studied
Interventions
- DRUG Simvastatin 40mg
Study Locations (1)
California
- Cedars Sinai Medical Center - Los Angeles
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-01-25 |
| Est. Completion | 2025-05-12 |
| Phase | Early Phase 1 |
What the finished NCT04457089 record still lists
NCT04457089 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 188-participant average among 6 other Recurrent Ovarian Cancer trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Recurrent Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Simvastatin 40mg is the first listed.
NCT04457089 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT04457089 about?
NCT04457089 is a clinical study titled "Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer". This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.
What is the current status of trial NCT04457089?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2021-01-25. Estimated completion is 2025-05-12.
What conditions does trial NCT04457089 study?
This clinical trial studies the following conditions: Recurrent Ovarian Cancer, Platinum-sensitive Ovarian Cancer.
What interventions are being tested in trial NCT04457089?
The interventions under investigation include: Simvastatin 40mg (DRUG).
Who is sponsoring clinical trial NCT04457089?
This trial is sponsored by Marc Goodman, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04457089 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RECRUITING · Phase 1
-
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
RECRUITING · Phase 2
-
Combination Therapy for Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
RECRUITING · Phase 1
-
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI